 Braxia Scientific Corp, a medical research company with clinics providing novel psychedelic treatments for depression, said it has closed a previously announced private placement of its common shares and warrants with institutional investors for gross proceeds of approximately C3 million. The Toronto-based company, which is primarily focused on owning and operating multidisciplinary clinics, said the net proceeds of the private placement will be used for expansion of clinics, certain strategic investments, and for general working capital purposes. 